Mastering MicroRNA and target gene network diagrams is not only conducive to research, but also can greatly save time for researchers. Earlier this month, Protheragen MedAI announces that it is now capable of providing a series of solutions related to microRNA and target gene network diagram.

MiRNA is a hot research topic in recent years. Recent studies show that miRNAs can inhibit the expression of many genes and can participate in a variety of biological processes including tumorigenesis. To better understand how the functions of experimentally validated cancer miRNAs and their gene targets might be integrated within the pathogenesis of cancers, a gene interaction network analysis should be performed.

“The reasonable construction of regulatory network models in the fields of computer and other fields through later experimental verification is expected to discover new regulatory pathways and laws from multiple angles and levels, providing a meaningful theoretical and experimental basis for the development of disciplines and disease treatment,” says a spokesperson from Protheragen MedAI.

With unparalleled expertise in this field, the Protheragen MedAI team can provide professional microRNA and target gene network diagrams, which has proven to be very useful for understanding the biochemical basis of physiological events at different stages of drug development.
And with its AI-powered drug discovery platform, the company can take advantage of its computational skills to integrate the miRNA-target enrichment analysis with a network-based visualization and analysis in order to tackle the prioritization problem of miRNA-target candidate interactions.

For more information about Protheragen MedAI’s capability concerning microRNA and target gene network diagram, please visit to learn more.

Author's Bio: 

About Protheragen MedAI
Protheragen MedAI is missioned to solve difficulties and challenges faced by pharmaceutical industry and accelerate drug discovery process by applying AI into processes and attempts like personalized healthcare and various other medical applications. To this end, a few AI-powered drug discovery platforms have been developed, including CADD Platform, AIDD Platform, and Experimental Validation Platform. All these platforms are conducive to the drug R&D projects of pharmaceutical companies. The good news is that Protheragen MedAI has successfully accomplished a few projects in the past few years, which helped pharmaceutical companies simplify R&D steps and at the same time helped streamline R&D costs and other input.